{"id":474851,"date":"2020-03-19T02:30:02","date_gmt":"2020-03-19T02:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474851"},"modified":"2020-03-19T02:30:02","modified_gmt":"2020-03-19T02:30:02","slug":"hidradenitis-suppurativa-hsmarket-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hidradenitis-suppurativa-hsmarket-insights-epidemiology-and-market-forecast2030_474851.html","title":{"rendered":"Hidradenitis Suppurativa (HS) – Market Insights, Epidemiology and Market Forecast- 2030"},"content":{"rendered":"
\"Hidradenitis<\/a><\/div>\n
DelveInsight\u2019s \u2018Hidradenitis Suppurativa (HS)-Market Insights, Epidemiology and Market Forecast-2030\u2019 report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Albany, US –<\/strong> DelveInsight launched its new report on Hidradenitis Suppurativa (HS)-Market Insights, Epidemiology and Market Forecast-2030<\/a>.<\/p>\n

DelveInsight’s ‘Hidradenitis Suppurativa (HS)-Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.<\/p>\n

The key facts of the report:<\/strong><\/p>\n

1. Hidradenitis Suppurativa total prevalent population in 7MM was found to be 6,851,308 in 2017.
2. Among all the countries, the United States accounts for the highest Hidradenitis Suppurativa prevalent population with 3,271,104 prevalent cases in the United States in 2017.
3. In 2017, there were 2,414,075, Hidradenitis Suppurativa prevalent cases in women and 857,029 prevalent cases in men in the United States.
4. Among the European countries, Germany had the highest prevalent population of Hidradenitis Suppurativa with 832,312 cases, followed by France in 2017. On the other hand, Spain had the lowest prevalent population in 2017.<\/p>\n

Key benefits of the report:<\/strong><\/p>\n

1. Hidradenitis Suppurativa market report covers a descriptive overview and comprehensive insight of the Hidradenitis Suppurativa epidemiology and Hidradenitis Suppurativa market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Hidradenitis Suppurativa market report provides insights on the current and emerging therapies.
3. Hidradenitis Suppurativa market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Hidradenitis Suppurativa market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa market.<\/p>\n

“Hidradenitis Suppurativa is more common (three times) in women than men.”<\/strong><\/p>\n

\"\"<\/strong><\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/hidradenitis-suppurativa-market<\/p>\n

The key pharma players involved in Hidradenitis Suppurativa market<\/strong> are:
1. InflaRx
2. Incyte Corporation
3. ChemoCentryx
4. XBiotech
5. Celgene
6. Novartis<\/p>\n

Drugs covered are:<\/strong>
1. IFX-1
2. INCB054707
3. Avacopan
4. MABp1
5. Cosentyx etc.<\/p>\n

Download free sample pages<\/strong> @https:\/\/www.delveinsight.com\/sample-request\/hidradenitis-suppurativa-market<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Key Insights<\/span>
2. Hidradenitis Suppurativa Market Overview at a Glance<\/span>
3. Hidradenitis Suppurativa Disease Overview<\/span>
4. Hidradenitis Suppurativa Epidemiology and Patient Population<\/span>
5. Hidradenitis Suppurativa Country Wise-Epidemiology<\/span>
5.1. United States<\/span>
5.2. EU5<\/span>
5.2.1.Assumptions and Rationale<\/span>
5.2.2.Germany<\/span>
5.2.3.UK<\/span>
5.2.4.France<\/span>
5.2.5.Italy<\/span>
5.2.6.Spain<\/span>
5.3. Japan<\/span>
6. Hidradenitis Suppurativa Current Treatment Practices<\/span>
7. Unmet Needs<\/span>
8. Hidradenitis Suppurativa Marketed Drugs<\/span>
8.1. Humira: AbbVie<\/span>
9. Hidradenitis Suppurativa Emerging Therapies<\/span>
9.1. Key Cross of Emerging Therapies<\/span>
9.2. IFX-1: InflaRx<\/span>
9.3. Cosentyx (Secukinumab): Novartis Pharmaceuticals<\/span>
9.4. MABp1 (Bermekimab): XBiotech, Inc.<\/span>
9.5. Avacopan: ChemoCentryx<\/span>
10. Hidradenitis Suppurativa 7 Major Market Analysis<\/span>
11. Market Outlook by Country<\/span>
12. The United States: Market Outlook<\/span>
13. EU-5 Countries: Market Outlook<\/span>
13.1. Germany Market Size<\/span>
13.2. France Market Size<\/span>
13.3. Italy Market Size<\/span>
13.4. United Kingdom Market Size<\/span>
13.5. Spain Market Size<\/span>
14. Japan: Market Outlook<\/span>
14.1. Japan Market Size<\/span>
15. Market Drivers<\/span>
16. Market Barriers<\/span>
17. Appendix<\/span>
18. DelveInsight Capabilities<\/span>
19. Disclaimer<\/span>
20. About DelveInsight<\/span><\/p>\n

Related reports:<\/strong><\/p>\n

Hidradenitis Suppurativa (HS) – Epidemiology Forecast to 2030<\/a><\/span><\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight\u2019s \u2018Hidradenitis Suppurativa (HS)-Market Insights, Epidemiology and Market Forecast-2030\u2019 report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-474851","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=474851"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=474851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=474851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=474851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}